On March 18, from 1-2pm ET, The National Coalition on Health Care and West Health co-hosted the first of a two-part, Hill briefing series: “The Burden of High Drug Prices on Communities of Color”.
The Path Forward: The 2020 Elections and Re-Imagining the Health Care System Amid Crisis
On October 1, NCHC held a virtual event bringing together expert perspectives on the Trump and Biden presidential campaigns to share the candidates’ plan to reinvent our nation’s health care system for our patients, providers, and communities. The conversation was moderated by Noam Levey, a national health care reporter with the Los Angeles Times, followed by another […]
NCHC: Drug Pricing Primer
High prescription drug prices contribute to high total health care costs in the United States. Prices in the United States are higher than any other developed country, outpacing the effects of volume, types of drugs, or population size on total drug spending. Retail prescription drugs accounted for 9% of the $3.6 trillion (17.7% of GDP) […]
NCHC Statement on the Pricing of Remdesivir
On Monday, June 29, Gilead announced the pricing of remdesivir, an anti-viral drug that treats COVID-19. The Coalition supports protecting consumers from unaffordable drug costs. The pricing decision will exacerbate the health care affordability crisis already plaguing the country’s response to COVID-19. Fundamentally, the United States needs to develop a fair drug pricing system that […]
The Hill: Re-Examining the Delivery of High-Value Care through COVID-19
On June 15, NCHC’s John Rother collaborated with Katy Spangler, the Co-Director of Smarter Health Care Coalition, and Dr. A. Mark Fendrick, the Director of the University of Michigan Center for Value-Based Insurance Design, to publish an article in The Hill about high-value care amidst COVID-19. COVID-19 has created unprecedented opportunities for change, including the […]
- 1
- 2
- 3
- …
- 9
- Next Page »